Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Details Narrative)

Stockholders Equity (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
Stockholders Equity (Details Narrative) - USD ($)	Feb. 16, 2021	Apr. 19, 2019	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2017
Conversion price			$ 3.40	$ 3.40
Common stock, par value			$ 0.001	$ 0.001		$ 0.001
Common stock shares granted for consultants	2,502,518
Fair value of stock options granted for consultants	$ 9,679,000
Proceeds from exercise of warrants				$ 16,433,000	$ 0
Common shares issued upon exercise of warrants				3,076,017
Common stock shares vested	1,829,620
Common stock shares vest over two years	672,898
Unvested shares of common stock				509,772
Fair value of stock options granted				$ 1,789,000
Issuance of Common Stock in public offering	4,945,000
Issuance of Common Stock in public offering, amount	$ 24,679,000
Purchase of warrants	5,192,250
Convertible note payable	$ 38,799,000		$ 38,799,000	38,799,000
Principal amount			33,272,000	33,272,000
Accrued interest			$ 0	0		$ 4,838,000
Debt conversion debt instrument , shares	11,413,322
Stock compensation expense				$ 7,890,000
Price per share	$ 5.50
Exercise price of warrant	$ 5.50
Shares of common stock issue			10,408,827	10,408,827
Notes payable related party			$ 35,383,000	$ 35,383,000
Unissued shares of common stock			1,004,495	1,004,495
Common stock shares issued upon submission of transfer agent				74,094
Common stock issuable amount				$ 3,416,000
Converted conversion of common stock	11,413,322
Common stock, Shares Issued During Period				1,992,746
Intrinsic value of warrants			$ 3,180,000	$ 3,180,000
Aggregate shares of common stock	5,192,250
Shares of common stock upon exercise of warrants				3,073,818
Shares of common stock upon exercise of warrants, amount				$ 16,433,000
Issuance of Common Stock for research and development agreement, amount			$ 327,000	$ 9,103,000	$ 180,000
Preferred stock, par value			$ 0.01	$ 0.01		$ 0.01
Common Stock Issuable
Convertible note payable			$ 3,416,000	$ 3,416,000
Accrued interest	$ 5,527,000
Consultants [Member]
Stock compensation expense				9,103,000
Fully vested shares, amount				$ 1,213,000
Series C Preferred Stock [Member]
Common stock, par value			$ 0.01	$ 0.01
Preferred stock, issued			96,230	96,230			96,230
Description of conversion ratio				The conversion ratio is based on the average closing bid price of the common stock for the fifteen consecutive trading days ending on the date immediately preceding the date notice of conversion is given, but cannot be less than $3.40 or more than $4.9113 for each share of Series C Preferred Stock. The conversion ratio may be adjusted under certain circumstances such as stock splits or stock dividends. The Company has the right to automatically convert the Series C Preferred Stock into common stock if the Company lists its shares of common stock on the Nasdaq National Market and the average closing bid price of the Company’s common stock on the Nasdaq National Market for 15 consecutive trading days exceeds $3,000.00. Each share of Series C Preferred Stock is entitled to the number of votes equal to 0.26 divided by the average closing bid price
Common Stock [Member]
Issuance of Common Stock for research and development agreement				189,753
Issuance of Common Stock for research and development agreement, amount				$ 1,355,000
Series J Preferred Stock [Member]
Conversion price	$ 3.40	$ 3.40
Preferred stock, issued			692,220	692,220
Preferred stock shares designated	2,000,000
Preferred stock, par value		$ 0.01
shares issued exchange of cancellation of indebtness		840,000		1,513,548
Beneficial conversion percantage		9.99%
Presferred stock shares outstanding			692,220	692,220
Public offering shares	2,353,548
Series K Preferred Stock [Member]
Preferred stock shares designated	115,000
Preferred stock, par value	$ 0.01